Skip to main content
Beth Christian, MD, Oncology, Columbus, OH

BethAnnChristianMD

Oncology Columbus, OH

Hematologic Oncology

Physician

Dr. Christian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Christian's full profile

Already have an account?

  • Office

    460 W 10th Ave
    Fl 5
    Columbus, OH 43210
    Phone+1 614-293-8619
    Fax+1 614-293-6420

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2006 - 2009
  • Ohio State University Hospital
    Ohio State University HospitalResidency, Internal Medicine, 2002 - 2005
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 2002

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2002 - 2025
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...
    Beth A. Christian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma
    Beth A. Christian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study
    Beth A. Christian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 StudiesClinically Re... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018